Research programme: CNS disorder therapeutics - Amylon Therapeutics

Drug Profile

Research programme: CNS disorder therapeutics - Amylon Therapeutics

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ProQR Therapeutics
  • Developer Amylon Therapeutics
  • Class Neuroprotectants; RNA
  • Mechanism of Action Amyloid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cerebral amyloid angiopathy; Hereditary-cerebral-hemorrhage-with-amyloidosis-Dutch-type

Most Recent Events

  • 12 Sep 2017 RNA-based therapy for treatment of Cerebral amyloid angiopathy licensed to Amylon Therapeutics
  • 12 Sep 2017 Early research in Cerebral amyloid angiopathy in Netherlands (unspecified route)
  • 12 Sep 2017 Early research in Hereditary cerebral hemorrhage with amyloidosis-Dutch type in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top